ImmunoPrecise Antibodies (IPA) Competitors $0.38 +0.02 (+5.19%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.02 (+4.69%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. IMMX, PEPG, NBRV, PDSB, STTK, MDCX, HOWL, ALVR, OKYO, and MRSNShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Immix Biopharma (IMMX), PepGen (PEPG), Nabriva Therapeutics (NBRV), PDS Biotechnology (PDSB), Shattuck Labs (STTK), Medicus Pharma (MDCX), Werewolf Therapeutics (HOWL), AlloVir (ALVR), OKYO Pharma (OKYO), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Immix Biopharma PepGen Nabriva Therapeutics PDS Biotechnology Shattuck Labs Medicus Pharma Werewolf Therapeutics AlloVir OKYO Pharma Mersana Therapeutics Immix Biopharma (NASDAQ:IMMX) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings. Which has higher earnings and valuation, IMMX or IPA? Immix Biopharma has higher earnings, but lower revenue than ImmunoPrecise Antibodies. Immix Biopharma is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$15.43M-$0.77-2.21ImmunoPrecise Antibodies$24.07M0.49-$20.13M-$1.16-0.33 Which has more risk and volatility, IMMX or IPA? Immix Biopharma has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Is IMMX or IPA more profitable? Immix Biopharma has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -114.50%. ImmunoPrecise Antibodies' return on equity of -73.74% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -102.68% -80.89% ImmunoPrecise Antibodies -114.50%-73.74%-42.68% Do analysts prefer IMMX or IPA? Immix Biopharma presently has a consensus price target of $7.00, suggesting a potential upside of 310.56%. ImmunoPrecise Antibodies has a consensus price target of $4.00, suggesting a potential upside of 956.52%. Given ImmunoPrecise Antibodies' higher probable upside, analysts plainly believe ImmunoPrecise Antibodies is more favorable than Immix Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer IMMX or IPA? In the previous week, ImmunoPrecise Antibodies had 9 more articles in the media than Immix Biopharma. MarketBeat recorded 11 mentions for ImmunoPrecise Antibodies and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.56 beat ImmunoPrecise Antibodies' score of -0.21 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ImmunoPrecise Antibodies 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of IMMX or IPA? 11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. 48.9% of Immix Biopharma shares are held by insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer IMMX or IPA? ImmunoPrecise Antibodies received 3 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 93.33% of users gave ImmunoPrecise Antibodies an outperform vote. CompanyUnderperformOutperformImmix BiopharmaOutperform Votes11100.00% Underperform VotesNo VotesImmunoPrecise AntibodiesOutperform Votes1493.33% Underperform Votes16.67% SummaryImmix Biopharma and ImmunoPrecise Antibodies tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.76M$6.76B$5.57B$7.94BDividend YieldN/A2.81%5.35%4.04%P/E Ratio-0.497.2023.5718.83Price / Sales0.49204.84369.2389.78Price / CashN/A65.6738.1634.64Price / Book0.416.116.694.19Net Income-$20.13M$142.11M$3.20B$247.10M7 Day Performance-11.44%-5.83%-3.80%-2.89%1 Month Performance10.31%-10.66%-0.41%-6.40%1 Year Performance-74.24%-12.18%9.29%0.33% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies1.9516 of 5 stars$0.38+5.2%$4.00+954.9%-76.4%$11.78M$24.07M-0.4980Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageGap DownIMMXImmix Biopharma2.8926 of 5 stars$1.68-1.2%$7.00+316.7%-44.9%$46.57MN/A-1.989News CoveragePEPGPepGen2.2126 of 5 stars$1.41-5.1%$10.33+635.5%-91.0%$45.93MN/A-0.4730News CoverageNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PDSBPDS Biotechnology1.8459 of 5 stars$1.19-5.6%$9.00+656.3%-73.1%$45.45MN/A-1.0320Earnings ReportShort Interest ↓STTKShattuck Labs2.5394 of 5 stars$0.95-9.9%$7.50+689.4%-90.5%$45.36M$5.72M-0.62100Earnings ReportAnalyst RevisionMDCXMedicus PharmaN/A$3.72+18.8%$10.00+168.8%N/A$44.35MN/A0.00N/AEarnings ReportPositive NewsGap UpHOWLWerewolf Therapeutics2.5234 of 5 stars$0.97-5.6%$9.00+825.7%-86.4%$43.58M$1.89M-0.6440ALVRAlloVir1.8641 of 5 stars$8.60-4.6%N/A-56.6%$43.37MN/A-0.43110OKYOOKYO Pharma3.1573 of 5 stars$1.27-5.9%$7.00+451.2%-19.7%$42.97MN/A0.007Positive NewsGap UpMRSNMersana Therapeutics4.3616 of 5 stars$0.34-9.3%$4.00+1,062.1%-92.4%$42.90M$40.50M-0.56150Short Interest ↓Gap Down Remove Ads Related Companies and Tools Related Companies Immix Biopharma Alternatives PepGen Alternatives Nabriva Therapeutics Alternatives PDS Biotechnology Alternatives Shattuck Labs Alternatives Medicus Pharma Alternatives Werewolf Therapeutics Alternatives AlloVir Alternatives OKYO Pharma Alternatives Mersana Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
